Advertisement
 
Disease Research
Subscribe to Disease Research

The Lead

Kala Advances Trials of Eye Drugs with $22.5M Financing

April 24, 2014 3:07 pm | News | Comments

Kala Pharmaceutical Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, announced it has completed a $22.5 million Series B financing. Read more...  

Celsion Updates Survival Data for Liver Cancer Drug

April 24, 2014 2:39 pm | News | Comments

Celsion Corporation announced that updated results from the 701 patient HEAT Study post-hoc...

FDA Approves First Castleman’s Disease Drug

April 24, 2014 2:19 pm | News | Comments

Janssen Biotech Inc. announced the U.S. Food and Drug Administration (FDA) has approved Sylvant...

Researchers Find New HIV Target

April 24, 2014 2:05 pm | News | Comments

Scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Lupin, Yoshindo Ink Joint Biosimilars Venture

April 24, 2014 10:39 am | News | Comments

Lupin Ltd. announced that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. to create a new entity, YL Biologics (YLB). Read more...             

Sinovac Wins China Government Grant for HFMD Vaccine

April 24, 2014 10:28 am | News | Comments

Sinovac Biotech Ltd. announced that it has received a government grant in China for construction of the company’s dedicated production facility for its Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Read more...    

Germany's Merck Posts Positive PKU Drug Results

April 24, 2014 10:12 am | News | Comments

Merck announced that the Phase 3b SPARK study has met its primary endpoint in children less than 4 years of age who have phenylketonuria (PKU). Read more...                            

Advertisement

Aspirin Reduces Colon Cancer Risk for Those with Specific Gene

April 24, 2014 10:02 am | News | Comments

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. Read more...  

Celgene Snags New Crohn's Disease Drug

April 24, 2014 9:48 am | News | Comments

Celgene Corp. entered into a global license agreement with Nogra Pharma Ltd. to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease. Read more...  

FDA Clears IND Amendment for Hematologic Cancer Drug

April 23, 2014 12:40 pm | News | Comments

Fate Therapeutics Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced that the FDA has cleared its IND amendment to evaluate Prohema in pediatric patients undergoing hematopoietic stem cell transplantation for hematologic malignancies. Read more...

Glaucoma Adjunct Restores Vision in Blinding Disorder

April 23, 2014 12:25 pm | News | Comments

An inexpensive glaucoma drug, acetazolamide, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health. Read more...

Bayer's Ciprofloxacin DPI Gets Orphan Drug Status

April 23, 2014 11:41 am | News | Comments

Bayer HealthCare announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis. Read more...

Advertisement

Lpath, Walter Reed Collaborate on Brain Injury Drug

April 23, 2014 11:23 am | News | Comments

Lpath Inc., the industry leader in bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement. Read more...

New Drugs Offer Hope for Migraine Prevention

April 23, 2014 11:11 am | News | Comments

Two new studies may offer hope for people with migraine. Both studies involve drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started. Read more...         

Sales of Controversial Hep C Drug Total $2.27B

April 23, 2014 11:08 am | News | Comments

Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi - launched in the United States during December and approved in Europe in January - totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. Read more...

Glioblastoma Vaccine Hits Primary Endpoints in Phase 1

April 23, 2014 11:03 am | News | Comments

Immatics Biotechnologies GmbH, Cancer Research UK and Cancer Research Technology announced that they have entered a license agreement to continue developing its cancer vaccine IMA950 for glioblastoma after positive results from a Phase 1 trial. Read more...

Blood Pressure Drug Prevents Epilepsy After Brain Injury

April 23, 2014 10:52 am | News | Comments

Between 10 and 20% of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. Read more...   

Advertisement

Bayer Submits Riociguat for PAH in Japan

April 23, 2014 10:42 am | News | Comments

Bayer HealthCare has filed riociguat for the treatment of pulmonary arterial hypertension (PAH) for regulatory approval in Japan. Read more...                               

Molecules Discovered for Neurodegenerative Diseases

April 22, 2014 1:02 pm | News | Comments

Researchers from NeuroPhage Pharmaceuticals Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. Read more...

NIH, Broadview Ventures Fund Stroke Study

April 22, 2014 12:33 pm | News | Comments

ZZ Biotech announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial evaluating the safety, tolerability and activity of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke. Read more...

AbbVie Submits NDA for Hep C Regimen

April 22, 2014 11:54 am | News | Comments

AbbVie submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. Read more...

Pfizer Reports Positive Phase 3 Results for Psoriasis Drug

April 22, 2014 11:46 am | News | Comments

Pfizer announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program evaluating the efficacy and safety of tofacitinib, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. Read more...

FDA Accepts Gilead NDAs for HIV Drugs

April 22, 2014 11:34 am | News | Comments

Gilead Sciences Inc. announced that the FDA has accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” agent, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. Read more...

On the Hunt for Safer Alternatives to NSAIDs

April 22, 2014 10:54 am | News | Comments

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure or sudden cardiac death. This has prompted a decade-plus search for safer, but still effective, alternatives to these drugs. Read more...

Zonegran Shows Promise in Children with Partial Epilepsy

April 22, 2014 10:26 am | News | Comments

Zonegran (zonisamide) is well tolerated and efficacious when used as an adjunctive (add-on) treatment for partial epilepsy, with or without secondary generalization, in children aged between six and 17 years for at least one year. Read more...  

GSK, Theravance Launch Phase 3 COPD Trial

April 22, 2014 10:15 am | News | Comments

GlaxoSmithKline and Theravance Inc. announced the start of a Phase 3 efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta-2 agonist (LABA), vilanterol (FF/VI). Read more...

Novartis Reshapes Business with GSK, Lilly Deals

April 22, 2014 9:28 am | by John Heilprin | News | Comments

Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more restructuring in the fast-changing industry. Read more...

Breaking News: Gastric Cancer Drug Approved

April 22, 2014 8:56 am | News | Comments

Lilly announced that the FDA has approved Cyramza for advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on/after prior fluoropyrimidine- or platinum-containing chemotherapy. Read more...

Questcor Reports Positive Results for Kidney Disease Drug

April 21, 2014 1:18 pm | News | Comments

Questcor Pharmaceuticals Inc. announced that results from an investigator-initiated clinical study of H.P. Acthar Gel in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN) have been published in the journal Nephrology Dialysis Transplantation. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading